EXTRACELLULAR CIRCULATING DNA IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: BIOLOGICAL CORRELATES AND PROGNOSTIC IMPACT
Author(s): ,
Dino Dujmovic
Affiliations:
Hematology,UHC Zagreb,Zagreb,Croatia
,
Sandra Bašić Kinda
Affiliations:
Hematology,UHC Zagreb,Zagreb,Croatia
,
Pavle Rončević
Affiliations:
Hematology,UHC Zagreb,Zagreb,Croatia
,
Antonela Samardžić
Affiliations:
Hematology,UHC Zagreb,Zagreb,Croatia
,
Ivo Radman
Affiliations:
Hematology,UHC Zagreb,Zagreb,Croatia
,
vedrana Škaro
Affiliations:
Molecular biology,PMF Zagreb,Zagreb,Croatia
,
Gordan Lauc
Affiliations:
Molecular biology,PMF Zagreb,Zagreb,Croatia
,
Klara Dubravčić
Affiliations:
Molecular biology,UHC Zagreb,Zagreb,Croatia
Igor Aurer
Affiliations:
Hematology,UHC Zagreb,Zagreb,Croatia
EHA Library. Dujmovic D. Jun 16, 2018; 215338; PS1014
Dino Dujmovic
Dino Dujmovic
Contributions
Abstract

Abstract: PS1014

Type: Poster Presentation

Presentation during EHA23: On Saturday, June 16, 2018 from 17:30 - 19:00

Location: Poster area

Background

Extracellular circulating DNA (cfDNA) can be found in small quantities in plasma of healthy persons, but higher concentrations are found in various disorders including malignant and autoimmune diseases, myocardial infarction, trauma, inflammation and complications of pregnancy. In patients with tumors, cfDNA is of tumor origin. Although it has been studied extensively in solid cancers, there is a dearth of information on cfDNA in hematologic neoplasia. 

Aims
The goal of this study was to determine the concentration of cfDNA in patients with lymphoma, its relation to demographic, biologic and clinical patient and tumor characteristics and to investigate its potential role as a marker of disease activity, prognosis or response to treatment.

Methods
The study was performed in  47  patients with diffuse B-large cell lymphoma from 2010-2013 lymphoma treated according to standard guidelines (Table 1). cfDNA concentration was determined using quantitative real-time PCR before and at the end of treatment.

Results
In DLBCL patients cfDNA concentration is somewhat higher than in healthy persons (median 24.6 ng/ml vs. 12.1 ng/ml), range from 0.45 ng/ml – 1675 ng/ml. In all patients cfDNA concentration correlated with unfavorable prognostic characteristics: age, LDH, beta-2 microglobulin, disease stage and IPI but not with Ki-67, gender or presence of extranodal disease. Correlation with beta-2 microglobulin was strongest. The conctration of cfDNA had no impact on survival(both OS and PFS). (Fig. 1). In multivariate analysis, cfDNA concentration was not an independent prognostic factor. In the vast majority of patients cfDNA concentrations at the end of treatment were lower than at the beginning but neither the absolute nor relative decline correlated with treatment outcomes.

Conclusion
In patients with diffuse large cell lymphoma, cfDNA concentration prior to treatment start correlates with negative prognostic factors, dominantly with those related to the total tumor mass. However, measuring cfDNA does not add independent clinically meaningful information and seems to be neither of diagnostic nor of prognostic value.

Session topic: 21. Aggressive Non-Hodgkin lymphoma - Clinical

Keyword(s): DLBCL

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies